A phase II study of ABI-007 in combination with Ramucirumab in patients with unresectable/recurrent gastric cancer refractory to prior chemotherapy containing fluoropyrimidines
Latest Information Update: 14 Aug 2018
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 03 Aug 2018 Status changed from active, no longer recruiting to completed.
- 17 Jan 2018 Primary endpoint (overall response rate (ORR))has been met, according to results published in the European Journal of Cancer.
- 17 Jan 2018 Results assessing the efficacy and safety of nab-paclitaxel plus ramucirumab combination therapy in patients with AGC refractory to firstline chemotherapy, were published in the European Journal of Cancer.